Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of JNJ-101556143 in metastatic androgen pathway modulation-resistant prostate cancer
jRCT2031260554Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HLD-0915 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
HLD-0915
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031260554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260554.